12:00 AM
 | 
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Anti-MIF mAb: Phase I started

Baxter began an open-label Phase I trial to evaluate IV anti-MIF mAb every 14 days in a 28-day cycle until disease progression or for up...

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >